Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature
Kitty Huang(Western University), David A. Palma(Western University), Gabriel Boldt(Cancer Care Ontario), Suresh Senan(Amsterdam UMC Location VUmc), Max Dahele(Amsterdam UMC Location Vrije Universiteit Amsterdam), Matthias Gückenberger(University of Zurich), Aaron D. Ward(Western University), George Rodrigues(London Health Sciences Centre)
Cited by 230
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k